Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

The Role of Organoids in Advancing Colorectal Cancer Research: Insights and Future Directions
Heydari, Zahra , Balaya, Rex Devasahayam Arokia , Sarkar, Gobinda , Boardman, Lisa, Devasahayam Arokia Balaya, Rex , Boardman, Lisa

Cancers | June 25, 2025 | Volume: 17 | Issue: 13 | Pages: 2129

10.3390/cancers17132129 | PMID 40647428 Get It

Organoids are three-dimensional (3D) structures that mimic the architecture and functionality of human organs, providing a novel approach to study diseases such as colorectal cancer (CRC). This review aims to explore the impact of organoids on understanding CRC and their potential use in exploring therapeutic outcomes. Colorectal cancer, characterized by the transformation of colonic epithelial cells into adenomas and carcinomas, remains one of the top causes of cancer-related morbidity and mortality worldwide. Traditional two-dimensional (2D) cell cultures fail to replicate the tumor microenvironment in an effective manner, which highlights the need for advanced 3D models. Organoids preserve the genetic and phenotypic properties of the original tumors, allowing for improved disease modeling, drug screening, and personalized medicine applications. When using patient-derived organoids (PDOs), researchers can gain insights into CRC initiation, progression, and treatment outcome. Ultimately, organoids represent an encouraging platform for improving therapeutic strategies for CRC, potentially leading to better patient outcomes through tailored treatment approaches.
Lichen planus pemphigoides: a retrospective single-centre cohort over two decades and comparison of idiopathic vs. drug-induced cases
Yang, Eilene, Lehman, Julia S. , Aghazadeh, Nessa , Todd, Austin, Damodaran, Sindhuja Sominidi, Lehman, Julia, Aghazadeh Mohandesi, Nessa , Sominidi Damodaran, Sindhuja , Lehman, Julia S , Imhof, Reese L. , Tekin, Burak

British Journal of Dermatology | June 25, 2025 | Volume: 193 | Issue: 4 | Pages: 784-786

10.1093/bjd/ljaf240 | PMID 40557943 Get It

We performed a retrospective review of patients with lichen planus pemphigoides (LPP) over almost a 23-year period to gather clinical, histopathological, immunological and treatment-related information and to compare idiopathic LPP with drug-induced LPP. This study represents the largest single-institution case series of LPP to date and includes novel findings related to mucosal involvement, autoantibody profiles and the value of monitoring bullous pemphigoid (BP) autoantibodies in predicting treatment response. This study also includes characteristic histopathological findings that can aid in the diagnosis and differentiation of LPP from BP, in addition to comparisons between idiopathic LPP and drug-induced LPP.
The hope and the hype of artificial intelligence for syncope management
Johnston, Samuel L. , Barsotti, Ercole John , Fedorowski, Artur , Ricci, Fabrizio , Heller, Eric G, Sheldon, Robert S. , Sutton, Richard , Shen, Win‐Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H. , Aburizik, Arwa , Haselton, Corey R, Cuskey, Alex J, Johansson, Madeleine , Dominic, Paari , Rao, B. Hygriv , Mudireddy, Avinash , Statz, Giselle M., Benditt, David G. , Gatti, Mauro , Menè, Roberto , Shiffer, Dana , Vassilikos, Vassilios , Bakogiannis, Constantinos , Fedorowski, Artur , Ricci, Fabrizio , Sheldon, Robert , Sutton, Richard , Shen, Win-Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H , Aburizik, Arwa , Lee, Sangil , Johansson, Madeleine , Macfarlane, Donald , Dominic, Paari , Abe, Haruhiko , Rao, B Hygriv , Mudireddy, Avinash , Sonka, Milan , Sandhu, Roopinder K , Kenny, Rose Anne , Gopinathannair, Rakesh , Benditt, David , Dipaola, Franca , Gatti, Mauro , Giaj Levra, Alessandro , Furlan, Raffaello , Ruwald, Martin H , Vassilikos, Vassilios , Gebska, Milena A , Olshansky, Brian , Cuskey, Alex, Lee, Sangil , Kenny, Rose Anne , Gopinathannair, Rakesh , Dipaola, Franca , Costantino, Giorgio , Furlan, Raffaello , Olshansky, Brian

European Heart Journal - Digital Health | June 25, 2025 | Volume: 6 | Issue: 5 | Pages: 1046-1054

10.1093/ehjdh/ztaf061 | PMID 40984999 Get It

Abstract Aims Syncope remains a diagnostic challenge despite advancements in testing and treatment. Cardiac syncope is an independent predictor of mortality and can be difficult to distinguish from other causes of transient loss of consciousness (TLOC). This paper explores whether artificial intelligence (AI) can improve the evaluation and management of patients with syncope. Methods and results We conducted a literature review and incorporated the opinions of experts in the fields of syncope and AI. The cause of TLOC is often unclear, hospitalization criteria are ambiguous, diagnostic tests are frequently non-informative, and assessments are costly. Patients are left with unanswered questions and limited guidance. Artificial intelligence (AI) has the potential to optimize syncope evaluation by processing large data sets, detecting imperceptible patterns, and assisting clinicians. However, AI has limitations, including errors, lack of human empathy, and uncertain clinical utility. Liability issues further complicate its integration. We present three viewpoints: (i) AI is crucial for advancing syncope management; (ii) AI can enhance the patient experience; and (iii) AI in syncope care is inevitable. Conclusion Artificial intelligence may improve syncope diagnosis and management, particularly through machine learning–based test interpretation and wearable device data. However, it has yet to surpass human clinical judgment in complex decision-making. Current challenges include gaps in understanding syncope mechanisms, AI interpretability, generalizability, and clinical integration. Standardized diagnostic approaches, real-world validation, and curated data sets are essential for progress. Artificial intelligence may enhance efficiency and communication but raises concerns regarding confidentiality, bias, inequities, and legal implications.
Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors
Cassier, Philippe A. , Borad, Mitesh J. , Sharma, Sunil , Dubois, Bertrand , Caux, Christophe , Okano, Fumiyoshi , Hoff, Daniel D. Von , Blay, Jean‐Yves , Von Hoff, Daniel D , Blay, Jean-Yves , Borad, Mitesh J

Cancer Research Communications | June 25, 2025 | Volume: 5 | Issue: 7 | Pages: 1119-1128

10.1158/2767-9764.crc-25-0123 | PMID 40557916 Get It

Abstract Purpose: TRK-950 is a first-in-class humanized antibody targeting cytoplasmic activation/proliferation-associated protein-1, which is strongly expressed on the cell membrane surface in or on most solid tumors but not in or on normal tissues. This first-in-human study investigated the safety profile, pharmacokinetics (PK), and preliminary antitumor activity. Patients and Methods: Patients with treatment-refractory, locally advanced, or metastatic solid tumors were enrolled in a dose escalation/expansion study. TRK-950 was administered intravenously weekly for 3 weeks in a 28-day cycle, with doses ranging from 3 to 30 mg/kg. Dose expansion included 10 mg/kg weekly and 30 mg/kg biweekly for colorectal cancer and 10 mg/kg weekly for cholangiocarcinoma. The primary objective of this study was to determine its safety, tolerability, and maximum tolerated dose. The secondary objectives were PK, preliminary antitumor activity, and identification of potential biomarkers. Results: Thirty-six patients received at least one dose of TRK-950. In the dose escalation cohort, the maximum tolerated dose was not reached, and no dose-limiting toxicities were observed up to 30 mg/kg. Common adverse events included abdominal pain, fatigue, constipation, back pain, nausea, and decreased appetite. TRK-950 exhibited a PK profile similar to that of other IgG subclass 1 therapeutic antibodies, with linear PK parameters over the 3 to 30 mg/kg dose range. The best response was stable disease. Notably, one patient with cholangiocarcinoma showed signs of cavitation after approximately 8 months, suggesting potential antitumor activity. Conclusions: TRK-950 is safe and well tolerated, has a favorable PK profile, and should be further investigated as a monotherapy and in combination with standard treatment for various types of solid tumors. Significance: TRK-950, a humanized antibody targeting CAPRIN-1, demonstrated good tolerability, no dose-limiting toxicities, a favorable PK profile, and potential antitumor activity in this first-in-human study. Currently, TRK-950 is undergoing Phase Ib and II trials for various cancers, showing promising development potential.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer
Russo, Suzanne , Anker, Christopher J. , Codipilly, Don C. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher L. , Kennedy, Timothy J., Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Jin, Zhaohui , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Small, William , Tchelebi, Leila T. , Simone, Charles B.

American Journal of Clinical Oncology | June 25, 2025 | Volume: 48 | Issue: 12 | Pages: 579-599

10.1097/coc.0000000000001222 | PMID 40557604 Get It

Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence. Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents. Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment. Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.
Tea and Tablets: What I Learned About Healing in Chupuro, Peru
Badell, Camila S. , Ponce, Oscar J. , Ruíz, Eloy , Ponce, Oscar Josue , Ruiz, Eloy F , Badell, Camila Sofía

Journal of the American Geriatrics Society | June 25, 2025 | Volume: 73 | Issue: 10 | Pages: 3259-3260

10.1111/jgs.19597 | PMID 40557593 Get It

Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma
Henrich, Ian C. , Billingsley, Margaret M. , Jain, Kanika , Mondal, Shreya , Quick, Laura , Young, Robert , Nguyen, Ngan , Oliveira, André M. , Blobel, Gerd A. , Mitchell, Michael J. , Chou, Margaret M. , Quick, Laura N , Jain, Kanika , Mitchell, Michael J , Young, Robert , Chou, Margaret M.

Molecular Cancer Therapeutics | June 25, 2025 | Volume: 24 | Issue: 11 | Pages: 1802-1814

10.1158/1535-7163.mct-24-0173 | PMID 40556502 Get It

Abstract Ewing sarcoma is an aggressive pediatric cancer that has remained refractory to current therapeutics. Immunotherapy has been unsuccessful in Ewing sarcoma, largely due to poor understanding of how its immune tumor microenvironment is regulated. We recently demonstrated that ubiquitin-specific protease 6 (USP6) can remodel the Ewing sarcoma immune landscape to engender an antitumorigenic tumor microenvironment. USP6 expression in Ewing sarcoma cells enhances surface expression of immunostimulatory ligands and receptors and induces production of multiple chemokines, driving recruitment and activation of tumor-suppressive immune lineages, including NK cells. We sought to harness this multifaceted immunostimulatory function into a novel therapeutic by delivering in vitro transcribed USP6 mRNA via ionizable lipid nanoparticles (LNP). Treatment of Ewing sarcoma cells with USP6 mRNA in vitro is capable of inducing the aforementioned antitumorigenic and immunostimulatory responses. In addition, USP6 mRNA–treated Ewing sarcoma cells elicit cytolytic activation of primary human CD8+ and CD4+ T lymphocytes and NK cells in vitro. Intratumoral delivery of USP6 mRNA LNPs suppresses growth of Ewing sarcoma xenografts, coincident with increased immune infiltration and activation. We further demonstrate that USP6 mRNA is capable of igniting an immunostimulatory program in other cancer types (including acute myeloid leukemia, melanoma, prostate cancer, head and neck cancer, and osteosarcoma) in vitro and suppressing acute myeloid leukemia xenograft growth in vivo. Treatment with USP6 mRNA LNPs was well-tolerated, with no observed gross toxicity. Together, these preclinical studies provide proof-of-concept for the immunogenic and antitumorigenic efficacy of USP6 mRNA LNPs and support its promise as a novel immunotherapeutic in diverse cancer types.
Lessons Learned Across Three Evaluations Incorporating Participant-Generated Photo Elicitation Interviewing
Berry, Carolyn A. , Abrams, Courtney , Paul, Margaret M. , Massar, Rachel E. , Fennelly, Kayla , Weitzman, Beth C. , Paul, Margaret M

American Journal of Evaluation | June 25, 2025 | Volume: 46 | Issue: 3 | Pages: 381-401

10.1177/10982140251335595 Get It

Qualitative interviews and focus groups are commonly used methods to elicit participants’ voices in program evaluations. However, the use of these data-gathering methods can fall short of the goal; even with open-ended questions, the protocols guiding and shaping interviews and focus groups heavily reflect the evaluators’ understanding and experience of the program or intervention under consideration and its target population(s). In this paper, we describe three cases that employed a method of inquiry that is underutilized in evaluation but one that we believe holds great potential as a method to enhance interpersonal reflexivity, namely participant-generated photo-elicitation interviewing (PEI). Across three diverse settings and interventions, we readily added participant-generated PEI to our mixed methods evaluations. We found participant-generated PEI to add great value to the evaluations by complementing our other data collection methods, allowing for greater participant voice, challenging evaluators’ assumptions, enhancing dissemination efforts, and fostering our reflexivity.
Infectious Complications and Mortality in Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation: Experiences of 10 Years in a Single Center
Cheema, Asfand Yar , Crilley, Thomas, Adcock, Bridget , Ardila, Valentina, Sheu, Micheal, García, S. Gómez , Majid, Aneela, Orland, Mark D. , Patel, Meera , Garcia, Sofia, Mushtaq, Ali , Majid, Aneela

No container title available | June 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6336582/v1 Get It

Abstract Background: Chronic immunosuppression in solid organ transplant recipients leads to B- and T-cell depletion, which increases the risk of somatic driver mutations that drive monoclonal lymphocyte proliferation. Paradoxically, this impairs cellular immunity, leading to increased susceptibility to both bacterial and viral pathogens. Methods: This retrospective cohort study evaluated solid organ transplant recipients diagnosed with post-transplant lymphoproliferative disorder (PTLD) at the Cleveland Clinic Foundation between January 1, 2010, and December 30, 2021. Patients aged ≥18 years with infection data available for at least one-year post-PTLD diagnosis were included, excluding hematopoietic stem cell transplant recipients. Data on PTLD subtype, Epstein-Barr virus (EBV) status, infectious complications, and outcomes were analyzed using univariate analysis (Pearson’s χ² test) and multivariable logistic regression to identify predictors of infections and mortality. Results: Among 98 PTLD cases, the median onset was 7.03 years post-transplant. EBV-positive PTLD had an onset of 6.97 ± 7.21 years, whereas EBV-negative cases occurred later (8.06 ± 5.24 years). Monomorphic PTLD (94.9%), particularly diffuse large B-cell lymphoma (DLBCL, 63.3%), was predominant. Infections occurred in 60% of patients post-PTLD, with bacterial (41.25%), viral (31.66%), fungal (25.9%), and parasitic (1.19%) infections. At one year, infection-related mortality (48%) exceeded PTLD progression-related deaths (36%). Conclusion: PTLD presents with a complex interplay of immunosuppression, malignancy, and infection. Infections, particularly bacterial infections, are major causes of morbidity and mortality. These findings highlight the need for vigilant infectious disease surveillance and tailored interventions to reduce infection-related mortality and improve outcomes in high-risk populations.
Gender-affirming interventions and prognosis in multiple sclerosis
Neyal, Nur , Nathoo, Nabeela , Kantarci, Orhun H. , Zeydan, Burcu , Zeydan, Burcu , Nathoo, Nabeela , Cathcart-Rake, Elizabeth

Multiple Sclerosis Journal | June 25, 2025 | Volume: 31 | Issue: 14 | Pages: 1672-1677

10.1177/13524585251341174 | PMID 40462266 Get It

Background: Gender-affirming hormone therapy (GAHT) may increase multiple sclerosis (MS) risk, yet MS disease course among transgender and gender-diverse (TGD) individuals remains understudied. We aimed to evaluate the disease course in TGD individuals with MS (TGD-MS). Methods: Seventeen TGD-MS were identified. Ten TGD-MS on GAHT (five transgender women with MS (TW-MS) and five transgender men with MS (TM-MS)) were investigated further for MS outcomes of symptomatic (clinical)/asymptomatic (radiological) disease activity and progressive MS (PMS) onset. Results: TW-MS (mean = 54.5 years, range = 35.1–66.3) were older than TM-MS (39.2 years, range = 29.6–47.2) at last follow-up. MS onset was later in TW-MS (31.5 years, range = 25.1–39.1) than in TM-MS (21.0 years, range = 15.0–29.8). Three patients (one TW-MS, two TM-MS) experienced symptomatic activity after GAHT initiation (8–10 months); in two patients (one TW-MS, one TM-MS), this marked symptomatic MS onset. Seven patients (four TW-MS, three TM-MS) had ⩾1 clinical/radiological disease activity. Four had PMS; all were TW-MS. In three, GAHT initiation preceded PMS onset (1–5 years). Disability was higher in TW-MS than in TM-MS. Conclusion: MS disease course may be modified by GAHT and may differ between TW-MS and TM-MS, highlighting the need for larger long-term studies to overcome disparities in MS care. Comprehensive GAHT history, timely management, and closer follow-up are warranted in TGD-MS.